Bergman Alan B. 4

What Happened

• Alan B. Bergman, Chief Financial Officer of 20/20 Biolabs, was granted a 100,000-share derivative award on 2026-04-02. The filing reports the acquisition price as $0.00 (no cash paid reported). This is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-02; Form 4 filed: 2026-04-06 (filed within the standard two-business-day window).
• Amount: 100,000 shares acquired as a derivative award; reported acquisition price $0.00.
• Vesting: 25,000 shares vest on the first anniversary of the grant; the remaining 75,000 vest in equal monthly installments over the following 36 months, subject to continuous service.
• Shares owned after transaction: Not stated in the provided filing.
• No 10b5-1 plan, tax-withholding, cashless sale, or late-filing flag noted in the supplied details.

Context

• This is a routine equity compensation grant used to retain or incentivize an executive and does not represent an open-market buy or sale. Such awards typically vest over time and depend on continued employment; they are informative about compensation but not a direct signal of immediate buying/selling by the insider.